InnovAge (INNV) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for December 4, 2025, to be held virtually, with voting on director elections and auditor ratification.
Stockholders of record as of October 14, 2025, are eligible to vote; proxy materials are available online.
Board recommends voting for three Class II director nominees and for the ratification of Deloitte & Touche LLP as independent auditor.
Voting matters and shareholder proposals
Proposals include electing three Class II directors for terms expiring in 2028 and ratifying Deloitte & Touche LLP as auditor for fiscal year ending June 30, 2026.
Voting is available online, by phone, mail, or during the virtual meeting; a plurality is required for director elections, and a majority for auditor ratification.
Deadlines for 2026 shareholder proposals: June 25, 2026 (Rule 14a-8) and September 4, 2026 (other proposals).
Board of directors and corporate governance
Board consists of nine directors divided into three classes, with staggered three-year terms.
Board includes a mix of independent and shareholder-affiliated directors; three women and one director with disabilities.
Principal Shareholders have significant nomination rights under a Director Nomination Agreement, with rights scaling down as ownership decreases.
Board committees: Audit, Compensation and Nominating, and Quality and Compliance, each with defined responsibilities and charters.
Board leadership structure separates Chair and CEO roles; annual self-evaluations and succession planning are in place.
Controlled company status under Nasdaq rules allows exemptions from certain governance requirements.
Latest events from InnovAge
- Q2 revenue and margins surged, raising full-year guidance despite ongoing cost and regulatory risks.INNV
Q2 20263 Feb 2026 - Care coordination, trust, and tailored technology are key to advancing aging-in-place models.INNV
7th Annual Healthcare Symposium3 Feb 2026 - Revenue up 11% with margin gains and positive Adjusted EBITDA; 2025 outlook remains strong.INNV
Q4 202421 Jan 2026 - Revenue up 12.4%, net loss halved, and Adjusted EBITDA margin improved to 3.2%.INNV
Q1 202516 Jan 2026 - Integrated care platform drives growth, margin expansion, and superior outcomes for complex seniors.INNV
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Revenue up 10.6% to $209M; FY2025 guidance reaffirmed amid margin and regulatory pressures.INNV
Q2 20259 Jan 2026 - Scale, technology, and insourcing drive growth and margin expansion in a supportive policy environment.INNV
KeyBanc Annual Health Care Forum 202526 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.INNV
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.INNV
Proxy Filing1 Dec 2025